UCB SA (OTCMKTS:UCBJY – Get Free Report) was the target of a large drop in short interest during the month of June. As of June 30th, there was short interest totaling 5,769 shares, a drop of 73.8% from the June 15th total of 21,989 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 70,017 shares, the short-interest ratio is presently 0.1 days.
UCB Stock Performance
Shares of UCB stock opened at $134.09 on Tuesday. The stock’s 50-day moving average is $144.02 and its 200 day moving average is $147.99. UCB has a one year low of $98.24 and a one year high of $168.76. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on UCBJY shares. Zacks Research upgraded UCB from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Barclays lowered UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 15th. Finally, Jefferies Financial Group upgraded UCB to a “moderate sell” rating in a report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.
About UCB
UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.
The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.
Further Reading
- Five stocks we like better than UCB
- Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings
- Insiders Sell 2 AI Enablers: Investors Can Buy Into Their Futures
- Beyond the Foundry: 5 Infrastructure Stocks Tackling the AI Bottlenecks
- These 3 Stocks Are Beating the Market in 2026 and Just Announced Hefty Dividend Increases
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
